Publication Name	World Journal of Clinical Oncology
Manuscript ID	94709
Country	United Arab Emirates

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients
Manuscript Source	Unsolicited Manuscript
All Author List	Naveed Syed, Ashish Vittalrao Chintakuntlawar, Deepti Vilasini, Aisha Mohamed Al Salami, Riad Al Hasan, Imrana Afrooz, Kanishka Uttam Chandani, Ashok Uttam Chandani and Aref Chehal
Funding Agency and Grant Number
Corresponding Author	Naveed Syed, Visiting Professor, Doctor, MBBS, Department of Hematology and Oncology, Sheikh Shakbout Medical City, Mafraq Area, Abu Dhabi 11001, United Arab Emirates. naveed3642003@gmail.com
Key Words	Homologous recombination repair; BRCA1; BRCA2; Homologous recombination deficiency; Ovarian cancer; Breast cancer; Poly (ADP-ribose) polymerase inhibitors; Olaparib; DNA double-strand breaks
Core Tip	Following National Comprehensive Cancer Network guidelines, breast cancer patients were tested for BRCA1/2 mutations, while ovarian cancer patients underwent homologous recombination defect testing. These mutations can be targeted with poly (ADP-ribose) polymerase inhibitor (PARPi) therapy, a form of precision medicine. In this single-center study, we analyzed the proportion of breast and ovarian cancer patients tested for mutations, demographics and disease characteristics of tested patients, and PARPi therapy outcomes. This first-of-its-kind study in the Middle East offers insights into targeted therapy use, contributing to knowledge on PARPis for breast and ovarian cancers.
Citation	<p>Syed N, Chintakuntlawar AV, Vilasini D, Al Salami AM, Al Hasan R, Afrooz I, Uttam Chandani K, Chandani AU, Chehal A. Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients. <i>World J Clin Oncol</i> 2024; 15(7): 848-858</p>

Received	2024-03-23 14:11
Peer-Review Started	2024-03-23 14:11
To Make the First Decision
Return for Revision	2024-05-03 19:39
Revised	2024-05-14 03:43
Second Decision	2024-06-14 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-06-14 08:09
Articles in Press	2024-06-14 08:09
Publication Fee Transferred	2024-06-18 02:59
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-07-09 00:24

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com